Healthcare

Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race

The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…

ByByAnuja Singh Mar 4, 2026

China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?

China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…

ByByAnuja Singh Mar 4, 2026

Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?

Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…

ByByAnuja Singh Mar 4, 2026

Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital or Closed Data Experiment?

Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…

ByByAnuja Singh Mar 4, 2026
Image Not Found

Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen Drug Deliver 15%+ Weight Loss and Redefine the $100B Obesity-Diabetes Market Dominated by Novo Nordisk A/S?

Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…

ByByAnuja Singh Mar 24, 2026

Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?

Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…

ByByAnuja Singh Mar 24, 2026
Scroll to Top